Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus

Status unconfirmed · Phase 4 · Has a placebo group

Conditions studied: Type 2 Diabetes

In brief

Investigators will be determining whether a once weekly injectable medication Bydureon versus placebo is able to reduce the development of atherosclerosis. Investigators are testing the overall hypothesis that 18 months of Bydureon treatment will improve cardiovascular risk factors, endothelial function and retard carotid atherosclerosis plaque progression in type 2 diabetes mellitus (T2DM). Investigators anticipate these studies will provide novel information about the temporal relationship between Bydureon induced changes in risk factors, endothelial function and atherosclerosis progression.

Key facts

Study ID

NCT02162550

Run by

Phoenix VA Health Care System

People needed

148

Starts

2014-06-01

Expected to finish

2019-09-01

Last updated by the study team

2018-06-14

Who can join

Age: 21 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• males and females of any race and ethnicity with T2DM, HbA1c of ≥6.5% and ≤10.0% on diet only
• take stable doses of oral antihyperglycemic agents with or without long-acting insulin
• must have a regular primary care provider (PCP) that is amenable to patient study participation and will facilitate (blinded to the treatment) the research team's study protocol efforts

You may not qualify if…

• type 1 diabetes mellitus (T1DM)
• current or recent glucagon-like peptide 1 receptor (GLP-1R) agonist use
• contraindications to MRI (e.g., claustrophobia, ferromagnetic materials, body habitus inappropriate for MRI exam)
• screening carotid ultrasound plaque thickness of <0.75 mm, prior or anticipated carotid stenting or endarterectomy
• recent CVD (past 6 months) or other major illness or conditions affecting risk (e.g., pancreatitis, severe renal disease) or personal or family history of medullary thyroid carcinoma
• patients with Multiple Endocrine Neoplasia syndrome type 2
• serious hypersensitivity to exenatide or any product components
• severe gastrointestinal disease, or pregnancy

Where it is running

• Phoenix VA Health Care System — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.